122225-33-6

Basic information

• Product Name: (R)-2-benzyl-4-tert-butoxy-4-oxobutanoic acid
• Synonyms: (R)-2-benzyl-4-tert-butoxy-4-oxobutanoic acid;(R)-2-Benzylbutanedioic acid 4-tert-butyl ester
• CAS NO: 122225-33-6
• Molecular Formula: C₁₅H₂₀O₄
• Molecular Weight: 264.319
• Mol File: 122225-33-6.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 400.4°C at 760 mmHg
• Flash Point: 143.8°C
• Appearance: /
• Density: 1.118
• Vapor Pressure: 3.94E-07mmHg at 25°C
• Refractive Index: 1.516
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: (R)-2-benzyl-4-tert-butoxy-4-oxobutanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-benzyl-4-tert-butoxy-4-oxobutanoic acid(122225-33-6)
• EPA Substance Registry System: (R)-2-benzyl-4-tert-butoxy-4-oxobutanoic acid(122225-33-6)

Safety Data

• Hazardous Substances Data: 122225-33-6(Hazardous Substances Data)

Usage

General Description

(R)-2-benzyl-4-tert-butoxy-4-oxobutanoic acid is a chemical compound that belongs to the class of organic compounds known as benzylamines. It is a derivative of benzoic acid, containing a benzyl group attached to the carboxyl group. (R)-2-benzyl-4-tert-butoxy-4-oxobutanoic acid also contains a tert-butoxy group and a 4-oxobutanoic acid functional group. It is commonly used as a building block in organic synthesis and as a precursor in the production of pharmaceuticals and agrochemicals. The compound has potential biological properties and may have applications in the development of new drugs and other therapeutic agents.

InChI:InChI=1/C15H20O4/c1-15(2,3)19-13(16)10-12(14(17)18)9-11-7-5-4-6-8-11/h4-8,12H,9-10H2,1-3H3,(H,17,18)/t12-/m1/s1

Upstream product

• 5292-43-3 bromoacetic acid tert-butyl ester 
• 116129-88-5 benzyl (2R)-2-<(tert-butyloxycarbonyl)methyl>-3-phenylpropionate 
• 1174275-13-8 4-(tert-butyl)-1-methyl-2-(dimethoxyphosphoryl)succinate 
• 100-52-7 benzaldehyde 
• 1229380-18-0 (R)-4-tert-butyl 1-methyl 2-benzylsuccinate 
• 116129-79-4 (4S)-3-<(2R)-2-<(tert-butyloxycarbonyl)methyl>-3-phenylpropionyl>-4-(2-propyl)oxazolidin-2-one 
• 136159-65-4 (S)-4-benzyl-3-(3-phenylpropanoyl)oxazolidin-2-one 
• 100-39-0 benzyl bromide 
• 49769-78-0 2-benzyl-malonic acid dimethyl ester 
• 287719-11-3 4-(4-benzhydryl-2-oxo-oxazolidin-3-yl)-4-oxo-butyric acid tert-butyl ester 
• 61996-82-5 C₁₆H₂₆O₇ 
• 645-45-4 hydrocinnamic acid chloride 
• 908290-75-5 (R)-3-(3'-phenylpropanoyl)-4-iso-propyl-6,6-dimethyl-(1,3)-oxazinan-2-one 
• 908290-87-9 (4R,2'R)-3-(4'-tert-butoxy-4'-oxo-2'-benzylbutanoyl)-4-iso-propyl-6,6-dimethyl-(1,3)-oxazinan 

Downstream Products

• 141215-90-9 1,1-dimethylethyl R-<<<1S-methyl-2-oxo-2-(phenylmethoxy)ethyl>amino>carbonyl> benzenebutanoate 
• 21307-97-1 (R)-2-benzylsuccinic acid 
• 168681-96-7 (2R)-3-cyclohexyl-2-t-butoxycarbonylmethyl-propanoic acid 
• 1229380-16-8 C₁₆H₂₂O₄ 
• 1229380-22-6 (R)-tert-butyl 3-benzyl-4-(4-(2-chlorophenyl)thiazol-2-ylamino)-4-oxobutanoate 
• 1229359-47-0 (R)-3-benzyl-4-((4-(2-chlorophenyl)thiazol-2-yl)(methyl)amino)-4-oxobutanoic acid 
• 1229361-86-7 (R)-3-benzyl-4-((4-(2-chlorophenyl)thiazol-2-yl)(cyclopropyl)amino)-4-oxobutanoic acid 
• 1229363-11-4 (R)-3-benzyl-4-(cyclopropyl-(4-(2,5-dichlorophenyl)thiazol-2-yl)amino)-4-oxobutanoicacid 

Relevant articles and documents

TARGETED PLASMA PROTEIN DEGRADATION

The present invention is directed to the bifunctional compounds and the use of such bifunctional compounds to lower plasma levels of extracellular target molecules by lysosomal degradation. Such bifunctional compounds have a cell surface receptor ligand covalently linked to a ligand that is capable of binding to an extracellular target molecule (such as a ligand for a growth factor, a cytokine, a chemokine, a hormone, a neurotransmitter, a capsid, a soluble receptor, an extracellular secreted protein, an antibody, a lipoprotein, an exosome, a virus, a cell, or a plasma membrane protein), where the cell surface receptor is associated with receptor mediated endocytosis, including asialoglycoprotein receptor (ASGPR) mediated lysosomal degradation and mannose-6-phosphate (M6PR) mediated lysosomal degradation. Pharmaceutical compositions comprising such bifunctional compounds and methods of treating a disease or disorder mediated by an extracellular molecule using such bifunctional compounds are also provided herein.

CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER

The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I):, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein X1, R1, R2, R3, R4, R5, R6, R6', R7, R7', R8, R9, R9', R10, R11, R12, and n are described herein.

COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS

The present invention is directed to novel compounds of formula (I) and their use in treating metabolic diseases.